PAVmed (PAVM)
(Delayed Data from NSDQ)
$1.72 USD
-0.05 (-2.82%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.74 +0.02 (1.16%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth C Momentum D VGM
PAVmed Inc. (PAVM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$6.50 | $9.00 | $4.00 | 267.23% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for PAVmed Inc. comes to $6.50. The forecasts range from a low of $4.00 to a high of $9.00. The average price target represents an increase of 267.23% from the last closing price of $1.77.
Analyst Price Targets (2 )
Broker Rating
PAVmed Inc. currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by two brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on two recommendations.
Of the two recommendations deriving the current ABR, one is Strong Buy, representing 50% of all recommendations. A month ago, Strong Buy represented 50%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/28/2024 | Maxim Group | Anthony V Vendetti | Strong Buy | Strong Buy |
3/19/2024 | Cantor Fitzgerald & Co | Ross Osborn | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 2 |
Average Target Price | $6.50 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 94 of 252 |
Current Quarter EPS Est: | NA |